Literature DB >> 28212998

What factors do patients consider most important in making lung cancer screening decisions? Findings from a demonstration project conducted in the Veterans Health Administration.

Sarah E Lillie1, Steven S Fu2, Angela E Fabbrini3, Kathryn L Rice4, Barbara Clothier5, David B Nelson2, Elizabeth A Doro5, M Anas Moughrabieh6, Melissa R Partin2.   

Abstract

INTRODUCTION: The National Lung Screening Trial recently reported that annual low-dose computed tomography screening is associated with decreased lung cancer mortality in high-risk smokers. This study sought to identify the factors patients consider important in making lung cancer screening (LCS) decisions, and explore variations by patient characteristics and LCS participation.
MATERIAL AND METHODS: This observational survey study evaluated the Minneapolis VA LCS Clinical Demonstration Project in which LCS-eligible Veterans (N=1388) were randomized to either Direct LCS Invitation (mailed with decision aid, N=926) or Usual Care (provider referral, N=462). We surveyed participants three months post-randomization (response rate 44%) and report the proportion of respondents rating eight decision-making factors (benefits, harms, and neutral factors) as important by condition, patient characteristics, and LCS completion.
RESULTS: Overall, the most important factor was personal risk of lung cancer and the least important factor was health risks from LCS. The reported importance varied by patient characteristics, including smoking status, health status, and education level. Overall, the potential harms of LCS were reported less important than the benefits or the neutral decision-making factors. Exposure to Direct LCS Invitation (with decision aid) increased Veterans' attention to specific decision-making factors; compared to Usual Care respondents, a larger proportion of Direct LCS Invitation respondents rated the chance of false-positive results, LCS knowledge, LCS convenience, and anxiety as important. Those completing LCS considered screening harms less important, with the exception of incidental findings.
CONCLUSION: Decision tools influence Veterans' perceptions about LCS decision-making factors. As the factors important to LCS decision making vary by patient characteristics, targeted materials for specific subgroups may be warranted. Attention should be paid to how LCS incidental findings are communicated. Published by Elsevier B.V.

Entities:  

Keywords:  Attitudes; Decision making; Early detection of cancer; Lung neoplasms

Mesh:

Year:  2016        PMID: 28212998     DOI: 10.1016/j.lungcan.2016.11.021

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  17 in total

1.  The complicated 'Yes': Decision-making processes and receptivity to lung cancer screening among head and neck cancer survivors.

Authors:  Aaron T Seaman; Kimberly Dukes; Richard M Hoffman; Alan J Christensen; Nicholas Kendell; Andrew L Sussman; Miriam Veléz-Bermúdez; Robert J Volk; Nitin A Pagedar
Journal:  Patient Educ Couns       Date:  2018-04-22

2.  Lung Cancer Screening Benefits and Harms Stratified by Patient Risk: Information to Improve Patient Decision Aids.

Authors:  Christina Bellinger; Paul Pinsky; Kristie Foley; Douglas Case; Ajay Dharod; David Miller
Journal:  Ann Am Thorac Soc       Date:  2019-04

Review 3.  Disparities in Lung Cancer Screening: A Review.

Authors:  Diane N Haddad; Kim L Sandler; Louise M Henderson; M Patricia Rivera; Melinda C Aldrich
Journal:  Ann Am Thorac Soc       Date:  2020-04

4.  Correction to: Development of Decisional Values Statements for Lung Cancer Screening among African American Smokers.

Authors:  Randi M Williams; Kenneth H Beck; James Butler; Sunmin Lee; Min Qi Wang; Kathryn L Taylor; Cheryl L Knott
Journal:  J Cancer Educ       Date:  2020-04       Impact factor: 2.037

5.  Evaluating Knowledge, Attitudes, and Beliefs About Lung Cancer Screening Using Crowdsourcing.

Authors:  John Monu; Matthew Triplette; Douglas E Wood; Erika M Wolff; Danielle C Lavallee; David R Flum; Farhood Farjah
Journal:  Chest       Date:  2020-02-07       Impact factor: 9.410

6.  Patient and Clinician Perspectives on Shared Decision-making in Early Adopting Lung Cancer Screening Programs: a Qualitative Study.

Authors:  Renda Soylemez Wiener; Elisa Koppelman; Rendelle Bolton; Karen E Lasser; Belinda Borrelli; David H Au; Christopher G Slatore; Jack A Clark; Hasmeena Kathuria
Journal:  J Gen Intern Med       Date:  2018-02-21       Impact factor: 5.128

7.  Development of Decisional Values Statements for Lung Cancer Screening Among African American Smokers.

Authors:  Randi M Williams; Kenneth H Beck; James Butler; Sunmin Lee; Min Qi Wang; Kathryn L Taylor; Cheryl L Knott
Journal:  J Cancer Educ       Date:  2020-04       Impact factor: 2.037

Review 8.  Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

9.  Challenges to Educating Smokers About Lung Cancer Screening: a Qualitative Study of Decision Making Experiences in Primary Care.

Authors:  Preston A Greene; George Sayre; Jaimee L Heffner; Deborah E Klein; Paul Krebs; David H Au; Steven B Zeliadt
Journal:  J Cancer Educ       Date:  2019-12       Impact factor: 1.771

10.  What is the effect of a decision aid on knowledge, values and preferences for lung cancer screening? An online pre-post study.

Authors:  Stephen D Clark; Daniel S Reuland; Alison T Brenner; Michael P Pignone
Journal:  BMJ Open       Date:  2021-07-09       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.